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Abstract
Introduction: MicroRNAs are small non-coding RNAs that are involved in the post-transcriptional negative
regulation of mRNAs. MicroRNA 510 (miR-510) was initially shown to have a potential oncogenic role in breast
cancer by the observation of its elevated levels in human breast tumor samples when compared to matched non-
tumor samples. Few targets have been identified for miR-510. However, as microRNAs function through the
negative regulation of their direct targets, the identification of those targets is critical for the understanding of their
functional role in breast cancer.
Methods: Breast cancer cell lines were transfected with pre-miR-510 or antisense miR-510 and western blotting
and quantitative real time PCR were performed. Functional assays performed included cell growth, migration,
invasion, colony formation, cytotoxicity and in vivo tumor growth. We performed a PCR assay to identify novel
direct targets of miR-510. The study focused on peroxiredoxin 1 (PRDX1) as it was identified through our screen
and was bioinformatically predicted to contain a miR-510 seed site in its 3’ untranslated region (3’UTR). Luciferase
reporter assays and site-directed mutagenesis were performed to confirm PRDX1 as a direct target. The Student’s
two-sided, paired t-test was used and a P-value less than 0.05 was considered significant.
Results: We show that miR-510 overexpression in non-transformed and breast cancer cells can increase their cell
growth, migration, invasion and colony formation in vitro. We also observed increased tumor growth when miR-
510 was overexpressed in vivo. We identified PRDX1 through a novel PCR screen and confirmed it as a direct
target using luciferase reporter assays. The reintroduction of PRDX1 into breast cancer cell lines without its
regulatory 3’UTR confirmed that miR-510 was mediating its migratory phenotype at least in part through the
negative regulation of PRDX1. Furthermore, the PI3K/Akt pathway was identified as a positive regulator of miR-510
both in vitro and in vivo.
Conclusions: In this study, we provide evidence to support a role for miR-510 as a novel oncomir. We show that
miR-510 directly binds to the 3’UTR of PRDX1 and blocks its protein expression, thereby suppressing migration of
human breast cancer cells. Taken together, these data support a pivotal role for miR-510 in breast cancer
progression and suggest it as a potential therapeutic target in breast cancer patients.
Keywords: MicroRNA, peroxiredoxin1, tumorigenesis, breast cancer, migration, miR-510
Introduction
Breast cancer is the most common cancer in women
worldwide, resulting in 350,000 deaths each year [1,2].
Most deaths due to breast cancer are the result of metasta-
sis, demonstrated by the drop in five-year survival from
90% to just 23% in women presenting with metastatic dis-
ease [3]. Metastasis involves epithelial-to-mesenchymal
transition (EMT) and cellular changes leading to a more
invasive phenotype. These invasive changes are critical
steps in breast cancer progression and can lead to treat-
ment failure [4]. A better understanding of the mechan-
isms underlying these phenotypic changes will allow
improved prediction of those patients susceptible to
metastasis as well as improved therapeutic strategies [1].
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Previous studies have suggested a role for microRNAs
in regulation of metastasis, invasion, proliferation, cell
cycle, growth, differentiation and apoptosis [5-8]. Micro-
RNAs (miRNAs) are small, non-coding RNA molecules
approximately 18 to 25 nucleotides in length [9]. They
comprise approximately 3% of the human genome and
regulate approximately 30% of transcripts [10,11].
Approximately half of miRNAs have been found in “fra-
gile sites”, regions associated with cancer [10]. miRNAs
negatively regulate expression of target genes by binding
to the 3’UTR of mRNA transcripts to either cause degra-
dation or prevent translation, depending upon comple-
mentarity [5,9]. miRNAs can regulate expression of many
different types of genes and have been shown to function
as both tumor suppressors and oncogenes [5,6,12].
Calin et al. [13] were the first to show involvement of
aberrant miRNA expression in cancer progression. Since
then, many studies have demonstrated that dysregulation
of miRNAs have implications in invasion, migration and
metastasis in breast cancer [7,14,15]. Our studies have
shown that miRNA 510 (miR-510), is elevated in breast
tumor samples while absent in the matched non-tumor
breast tissue samples [15]. These studies identify Peroxir-
edoxin 1 (PRDX1) as a novel direct target of miR-510.
PRDX1 is a member of a family of peroxidases with six
isoforms known to be involved in protection of cells
against oxidative stress [16,17]. Deletion of PRDX1 has
been shown to promote tumor growth in mice [18]. It is
ubiquitously and highly expressed and functions as a
tumor suppressor [18,19]. The goal of this study was to
investigate the role of miR-510 in breast cancer cell
migration and tumor growth and to verify PRDX1 as the
direct miR-510 target underlying the mechanism of these
phenotypic changes.
Materials and methods
Cell culture and reagents
Human breast cancer cell lines (MCF7, CAMA-1, MDA-
MB-231, MCF10A and BT549) were cultured and main-
tained at 37°C with 5% CO2 in medium supplemented
with 10% fetal bovine serum and 100 U of penicillin/
streptomycin. MCF7, CAMA-1, MDA MB 231 and
HEK293 cells were grown in DMEM media. BT549 cells
were grown in RPMI media. MCF10A cells were grown
in DMEM:F12 (50:50) media. MCF7 media was supple-
mented with 1 mM sodium pyruvate, 1 mM sodium
bicarbonate, 2 mM L-glutamine, 0.1 mM nonessential
amino acids and 0.01 mg/mL insulin. MCF10A media
was supplemented with 2 mM L-glutamine, 5% horse
serum, 10 μg/mL insulin, 20 ng/mL epidermal growth
factor (EGF), 500 ng/mL hydrocortisone, and 10 μg/mL
cholera toxin. The breast cancer cell line CAMA-1 was a
kind gift of R. Neve (University of California, San Fran-
cisco, CA, USA). All other lines were obtained from
ATCC (Manassas, VA, USA). Ethical approval for our
work with human breast cancer cell lines was not
required for our in vitro studies. All tissue culture
reagents were purchased from Invitrogen (Carlsbad, CA,
USA). shPrdx1 vectors were obtained from the Hollings
Cancer Center shRNA core laboratory (Medical Univer-
sity of South Carolina, Charleston, SC, USA).
Immunohistochemistry
Antigen retrieval was done by heating in a microwave
oven for 2 × 3 minutes on 30% power in 10 mmol/L
citrate (pH 6.0), followed by 30 minutes in a steamer.
Sections were washed, treated with 0.3% H2O2 for 30 min-
utes and non-specific binding was blocked with 2.5%
horse serum (ImmPRESS Vector staining kit; Vector
Laboratories, Burlington, CA, USA) for 20 minutes and
then incubated overnight at 4°C with Ki67 or p-Akt pri-
mary antibody at a 1:200 and 1:50 dilution, respectively, in
2.5% normal horse serum in PBS. Overnight incubation at
4°C was followed by 3 × 10-minute washes in PBS, Imm-
press anti-rabbit secondary antibody was incubated (Vec-
tor Laboratories) for 30 minutes at room temperature.
After washing with H2O, 3,3’-diaminobenzidine substrate
(Sigma, St Louis, MO, USA) was added for two minutes
followed by washing in H2O. Slides were counterstained
with hematoxylin.
Quantitative reverse transcription PCR
Total RNA from cancer cell lines was extracted using the
RNeasyPlus Mini Kit (Qiagen, Valencia, CA, USA). Total
RNA measuring 1 μg was reverse transcribed in a 20 μl
reaction using iScript (Bio-Rad, Hercules, CA, USA). Real
time PCR for gene expression was performed with 5 μl of
a 1:20 dilution of reverse transcribed cDNA using the uni-
versal probe library (UPL) system (Roche, Nutley, NJ,
USA) in a LightCycler 480 (Roche). The cycling conditions
were performed as per the manufacturer’s instructions.
Primer sequences for PRDX1 were: forward 5’-cactgacaaa-
catggggaagt-3’ and reverse 5’-tttgctcttttggacatcagg-3’
together with UPL probe #20; and for Akt1 forward
5’-gcagcacgtgtacgagaaga-3’ and reverse 5’-ggtgtcagtctcc-
gacgtg-3’ together with UPL probe #45. Triplicate
reactions were run for each cDNA sample. The relative
expression of each gene was quantified on the basis of Ct
value measured against an internal standard curve for
each specific set of primers using the software provided by
the instrument manufacturer (Roche). These data were
normalized to GAPDH using the primer sequences: for-
ward 5’-agccacatcgctcagacac-3’ and reverse 5’-gcccaatac-
gaccaaatcc-3’ together with UPL probe #60.
Taqman analysis
For microRNA analysis RNA was extracted as described
above using the RNeasyPlus Mini Kit from Qiagen.
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Total RNA measuring 100 ng was reverse transcribed
using miR-510 specific primers using the Applied Bio-
systems (Grand Island, NY, USA) reverse transcription
kit as per the manufacturer’s instructions. Real time
PCR was performed with 1 μl of reverse transcribed
cDNA using the TaqMan Assay from Applied Biosys-
tems as per the manufacturer’s instructions on the
Roche LightCycler 480.
Generation of stable cell lines
The cloning of miR-510 into pSuppressor-neo vector is
already described [15]. For the generation of clonal
stable MCF10A cells overexpressing miR-510 (510-1;
510-10; 510-11), pSuppressor-neo vector (Imgenex, San
Diego, CA, USA) expressing miR-510 was transfected
into MCF10A cells and stable cells were selected in
medium containing G418. The wild type 3’UTR of
PRDX1 was cloned into the XbaI site of the pGL3-pro-
moter vector (Promega, Madison, WI, USA) using the
primers PRDX1_3UTRf 5’-gcgctctagagcgctgggctgt-3’ and
PRDX1_3UTRr 5’-gcgctctagagactcatcaaggtctcagt-3’. The
sequence complementary to the seed of miR-510 was
deleted with the primers PRDX1mutF 5’-ttggtaggaatggcc
tggcgttgtgggcag-3’ and PRDX1mutR 5’-ctgcccacaacgccaggc-
cattcctaccaa-3’ using a QuikChange Site-Directed Muta-
genesis Kit (Stratagene, La Jolla, CA, USA). All constructs
were validated by sequencing at MWG Operon (Huntsville,
AL, USA).
Lentiviral stable pools
Stable expression of miR-510 in MCF10A, MCF7 and
MDA MB 231 cells was achieved through lentiviral
infection. Stable expression was achieved through selec-
tion in puromycin (Invitrogen). Lentiviral miR-510 and
control vectors (pEZX) were purchased directly from
GeneCopoeia (Rockville, MD, USA) and lentiviral pre-
parations were made using the Maine Medical Center
Research Institute cell culture and viral vector core
(Scarborough, ME, USA).
Oligonucleotide transfection
The miRNA inhibitors (Ambion, Austin, TX, USA) are
single-stranded chemically enhanced oligoribonucleo-
tides designed to inhibit the endogenous miRNAs. Cells
were transfected with the indicated amounts of oligori-
bonucleotide using the XtremeGene siRNA reagent as
per the manufacturer’s instructions (Roche). A total of
48 or 72 h after transfection, cells were harvested for
protein or RNA extraction and/or assay.
Plasmid transfection
Transient transfections were performed with the indicated
amounts of vector using the XtremeGene HP reagent as
per the manufacturer’s instructions (Roche). A total of 48
or 72 hours after transfection, cells were harvested for pro-
tein or RNA extraction and/or assay.
Luciferase assays
Cells were plated at 50,000 cells per well in a 24-well
plate. The pGL3 reporter constructs (0.5 μg, firefly luci-
ferase) were co-transfected with pRL-TK (0.05 μg,
Renilla luciferase) using NanoJuice as per the manufac-
turer’s instructions (Novagen, Gibbstown, NJ, USA).
Luciferase activity was measured after 48 h using the
dual luciferase reporter assay system (Promega). Firefly
luciferase activity was normalized to Renilla luciferase
activity for each transfected well.
Western blot analysis
Cell lysate preparation and Western blot analysis using
enhanced chemiluminescence were performed as
described previously [15]. Experimental antibodies
include human PRDX1 (Abcam, Cambridge, MA, USA).
GAPDH and beta-actin (Abcam) were used as loading
controls.
Pacman (haptokinetic) migration track assay
Wells within a two-well chamber slide were pre-coated
with 5 μg/mL fibronectin and then overlaid with a field
of 1 μm in diameter carboxylate-modified polystyrene
fluorescent microspheres (Invitrogen). Cells were then
seeded at low density (approximately 4/mm2) in normal
growth medium and incubated for a period of 24 h. The
ability of the cells to create nonfluorescent tracks was
then assessed by fluorescent microscopy and quantified
using NIH image. Error bars represent the SD from 10
migration tracks in three separate experiments.
Transwell migration and invasion assay
Cells were seeded into the upper chamber of a Transwell
insert pre-coated with 5 μg/ml fibronectin for migration
or a BD™Matrigel invasion chamber for invasion, in
serum-free medium at a density of 50,000 cells per well
(24-well insert; pore size, 8 μM; BD Biosciences, San Jose,
CA, USA). Medium containing 10% serum was placed in
the lower chamber to act as a chemo-attractant, and cells
were further incubated for 4 h (migration) and 24 h (inva-
sion). Non-migratory cells were removed from the upper
chamber by scraping with a cotton bud. The cells remain-
ing on the lower surface of the insert were stained using
Diff-Quick (Dade Behring, Inc., Newark, DE, USA). Cells
were quantified as the number of cells found in five ran-
dom microscope fields in two independent inserts. Error
bars represent the SD from three separate experiments.
Colony formation assay
Wild-type and miR-510 stably transformed MCF10A cells
were seeded at a cell density of approximately 4 cells/mm2
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in normal growth media. Cells were incubated as normal,
and colonies were counted after 7 to 10 d.
Cell growth assay
Cell growth was measured using the SRB assay [20].
Cells were plated into each well of a 96- well plate and
cells were fixed at the indicated time points with ice-
cold 5% trichloroacetic acid (TCA), washed and stained
with sulforhodamine B (SRB) and the optical density
was measured at 560 nm.
Trypan blue/cell viability assay
Cells were either untreated or treated with 50 μM for
24 hours. Cells were collected by trypsinization and
20 μl was mixed 1:1 with trypan blue and counted on
an automated cell counter.
Tumor growth
A total of 1 × 106 MDA-MB-231 cells stably transfected
with either miR-510 or scramble control were injected
orthotopically into eight-week-old female nude mice.
Tumors were measured biweekly with electronic calipers
and tumor volume calculated using the formula (L × W2)/2.
In vivo protocol approval
Research protocols were designed and conducted in
accordance with the guidelines set by the Institutional
Animal Care and Use Committee, Medical University of
South Carolina, Approval # ARC-2907.
Statistical analysis
For statistical testing, two-sided paired Student’s t-tests
were done using an Excel spreadsheet. P-values are
given for each individual experiment, but in general,
P < 0.05 was considered statistically significant. Error
bars represent standard deviations of three independent
experiments unless indicated otherwise.
Results
MicroRNA 510 promotes proliferation, migration,
invasion and colony formation in vitro
Our previous studies have shown that transient miR-510
expression increases the migration and invasion of non-
invasive MCF7 breast cancer cells [15]. However, the func-
tional effects of miR-510 expression in non-transformed
breast cells have not been assessed. To assess whether
migration and/or invasion are altered in miR-510 overex-
pressing MCF10A cells, we performed transwell migration
assays across a chemokine gradient, and invasion assays
through Matrigel. The number of cells found to migrate
or invade in miR-510 overexpressing cells was significantly
increased compared with the parental control. Using three
mir-510 independent clones we observe a two- to four-
fold increase in migration (Figure 1A) and four- to five-
fold increase in invasion (Figure 1B) across coated mem-
branes. To further explore the contribution of miR-510 to
cancer progression, we investigated the ability of the stably
transfected MCF10A cells to proliferate when seeded at
low density in vitro using a clonogenic assay and observed
an increase in the total number of colonies formed when
compared with the parental control (Figure 1C). Colony
formation was increased two- to six-fold in the mir-510
stably expressing clones. To assess the functional effects of
miR-510 when expressed at more physiological levels, we
established stable breast cell lines expressing miR-510
after lentivirus transduction. These included the non-
transformed MCF10A cells, the non-invasive MCF7 and
the invasive MDA MB 231 cancer cells. Proliferation and
migration are two major cellular processes that are
required for tumor growth and metastasis. Therefore, to
assess the role of miR-510 in the regulation of these
important processes, we first measured the ability of miR-
510 to increase migration in 1) non-transformed breast
(MCF10A), 2) non-invasive breast cancer (MCF7) and 3)
invasive breast cancer (MDA MB 231) cells. miR-510
expression was able to increase the ability of MCF10A
cells (Figure 1D) and MCF7 cells (Figure 1E) to migrate in
the absence of a stimuli as assessed by the Pacman hapto-
kinetic migration track assay (Additional file 1, Figure S1).
Similarly, miR-510 was able to increase the migration of
MDA MB 231 cells (Figure 1F) in the presence of a stimu-
lus as assessed by transwell migration assay. Reciprocal to
this we found that inhibition of miR-510 by transfection
with either antisense oligonucleotides (ASO-510) or anti-
miR510 vector (anti-510) in the breast cancer cell lines
CAMA-1 (Figure 1G) and BT549 (Figure 1H) was able to
inhibit migration in the presence of a stimuli as assessed
by transwell migration assay. Proliferation was assessed in
breast cell lines that were stably infected with miR-510
over a course of seven days (Figure 2) and we observed a
significant increase in the rate of cellular proliferation in
MCF10A (Figure 2A), MCF7 (Figure 2B) and MDA MB
231 (Figure 2C) miR-510 expressing cells when compared
to the scramble controls.
MicroRNA 510 expression is regulated by the AKT
Pathway
To determine which signaling pathways were involved in
the activation of miR-510 we performed a luciferase
reporter screening assay utilizing a construct that con-
tains a functional miR-510 seed sequence site [15]. We
treated the cells with a panel of kinase inhibitors and
measured luciferase expression compared to untreated
controls. We observed an increase in luciferase activity in
the cells treated with the PI3K inhibitor LY294002 when
compared to the untreated control, suggesting that the
PI3K/Akt pathway might be involved in the activation of
miR-510 expression (data not shown). To test this
Guo et al. Breast Cancer Research 2013, 15:R70
http://breast-cancer-research.com/content/15/4/R70
Page 4 of 13
Figure 1 MicroRNA 510 promotes migration, invasion and colony formation in vitro. Transwell migration (A), matrigel invasion (B) and
colony formation (C) assays of 3 independent stable clones over-expressing miR-510 (510-1, 510-10 and 510-11) compared to vector control
(pSupp-4). Quantitation of haptokinetic migration (Pacman) assay of MCF10A (D) and MCF7 (E) cells stably infected with miR-510 (510) compared
to stable infected scrambled control (scr). (F) Transwell migration assay of MDA MB 231 cells stably infected with miR-510 (510) compared to
stable infected scrambled control (scr). (G) Transwell migration assay of CAMA-1 cells transfected with antisense oligonucleoteide against miR-
510 (ASO-510) or scrambled control (scr). (H) Transwell migration assay of BT549 cells transfected with increasing concentrations of anti-miR-510
vector (anti-510) or scrambled vector control (scr). *P < 0.05.
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hypothesis, we transiently overexpressed Akt1 in
MCF10A cells and performed real time PCR to assess
miR-510 expression levels (Figure 2D). We observed a
significant (approximately seven-fold) increase in miR-
510 levels in MCF10A cells overexpressing Akt1 com-
pared to the empty vector control. To examine the role
of Akt1 in the regulation of miR-510 expression we
transfected MDA MB 175 VII cells, which express miR-
510 at relatively high levels, with a short hairpin vector
targeting Akt1 (shAkt1; Figure 2E, F). We performed real
time PCR to assess miR-510 expression levels (Figure 2F)
and observed a decrease in the levels of miR-510 in the
shAkt1 transduced cells when compared to the
scrambled control. Taken together these data suggest
that the PI3K/Akt pathway may function in the activation
of miR-510 in breast cancer.
MicroRNA 510 promotes tumor growth in vivo
To assess the functional effects of miR-510 in vivo, we
injected nude mice orthotopically with MDA MB 231
cells stably infected with miR-510 or scramble control
as described above. Tumor growth was monitored twice
weekly for 30 days. Tumors from both miR-510 expres-
sing and scrambled controls appeared to initiate at a
similar time frame. However, by three weeks the miR-
510 expressing tumors were growing more rapidly and
by the end of the study, the miR-510 expressing tumors
were larger (tumor volume) and heavier (tumor weight)
than the scrambled controls (Figure 3A, B). Histologi-
cally, the tumors looked similar; however, Ki67 staining
showed that the miR-510 expressing tumors were more
proliferative than the scrambled controls (Figure 3C, D).
Based on our in vitro observations with the PI3K/Akt
pathway and miR-510 expression, we performed IHC
with p-Akt and observed an increased level of phos-
phorylated or active Akt in tumors expressing miR-510
(Figure 3C).
Peroxiredoxin 1 is a direct target of miR-510
A PCR-based screen [21] was performed in order to
identify novel targets of miR-510, as microRNAs are
mainly thought to exert their effects through their
Figure 2 MicroRNA 510 increases cellular proliferation in vitro. Cellular proliferation of stable infected miR-510 (light gray lines) MCF10A (A),
MCF7 (B) and MDA MB 231 (C) cell lines compared to stable infected scrambled control (dark gray lines). (D) qPCR of miR-510 levels in MCF10A
cells transiently transfected with Akt1 or vector alone (EV). qPCR of Akt1 (E) and miR-510 (F) levels in MDA-MB-175 VII breast cancer cells
transduced with short hairpin Akt1 (shAkt) or scrambled control (scr). *P < 0.05.
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negative regulation and direct binding to the 3’UTR of
their target mRNA. Peroxiredoxin 1 (Prdx1) is bioinfor-
matically predicted and was identified through our
screen to be a direct target of miR-510 (Figure 4A;
Additional file 2, Table S1). We performed Western blot
(Figure 4B) and qPCR (Figure 4C, D) to assess the levels
Figure 3 MicroRNA 510 increases tumor growth in vivo. Panels show tumor volume (A), tumor weight (B), Immunohistochemistry (C) and
Ki67 quantitation (D) of tumors resulting from orthotopic injection of miR-510 (510) or scrambled control (scr) stably infected MDA MB 231 cells
into female nude mice.
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of endogenous PRDX1 and miR-510 levels in the various
breast cell lines used in the study. Prdx1 is an abundant
antioxidant protein and we found that it was present in
all cell lines examined (Figure 4B), but found no direct
correlation between miR-510 and Prdx1 levels in the
cell lines we examined (Figure 4B, D). To validate Prdx1
as a miR-510 target, and to examine whether Prdx1
expression is repressed by miR-510 through the pre-
dicted elements, a luciferase reporter construct contain-
ing the 3’ UTR of Prdx1 was transfected into HEK293
cells (Figure 4E). The presence of the 3’UTR of Prdx1
(PRDX 3’UTR) led to a decrease in luciferase expression
when compared to the empty vector (EV) control. The
most important criteria for target recognition are the 5’
five to eight nucleotide core sequence of a miRNA,
known as the “seed sequence.” To further validate that
the predicted miR-510 seed sequence within the PRDX1
3’UTR was functional, we mutated the seed sequence of
miR-510 in the luciferase reporter construct. Transfec-
tion of HEK293 cells with the mutated luciferase repor-
ter construct (PRDX mut) resulted in an increase in
luciferase activity when compared to the WT Prdx1
3’UTR (Figure 4E). Mutation of the seed sequence of
miR-510 within the 3’UTR did not fully restore lucifer-
ase activity to the levels observed in the cells transfected
with no 3’UTR construct, suggesting that other miRNA
binding sites are present and functional within the
3’UTR of PRDX1. To determine whether the PRDX1
3’UTR was responsive to miR-510 expression we trans-
fected MDA MB 231 cells stably infected with miR-510
or scrambled controls with the luciferase reporter vec-
tors (Figure 4F). We observed an increased repression of
the PRDX1 3’UTR when miR-510 was expressed when
compared to the scrambled controls. However, no
further significant decrease in luciferase activity was
observed in either the cells transfected with the PRDX
mut construct or the EV control suggesting that miR-
510 directly binds to the predicted site within the
3’UTR of PRDX1 to negatively regulate its expression.
To assess the effects of miR-510 on endogenous Prdx1
expression, both protein and RNA levels were assessed in
MCF10A, MCF7 and MDA MB 231 cells. We observed a
decrease in the levels of Prdx1 protein in all of the cells
tested when miR-510 was expressed, whereas the levels of
Prdx1 mRNA were relatively unchanged, suggesting that
miR-510 regulates Prdx1 through translational repression
as opposed to mRNA degradation (Figure 5A, B). CAMA-
1 and BT549 breast cancer cells were used as a model sys-
tem to look at loss of function as they express miR-510 at
the highest levels of all the breast lines examined. Trans-
fection of antisense oligoribonucleotides (ASO) targeted
against miR-510 (ASO-510) in CAMA-1 cells and anti-
miR510 vector (anti-510) in BT549 cells resulted in an
increase in Prdx1 protein levels, whereas the Prdx1 mRNA
levels remained unchanged (Figure 5C, D).
Prdx1 expression inhibits miR-510-mediated cell
migration
miRNAs have multiple targets and, therefore, the effects
observed after miR-510 expression may be the result of
the increased Prdx1 protein, as well as non-Prdx1-
related miR-510 effects. One way to evaluate these pos-
sibilities is to examine the phenotypes in cells in which
a non-targeted Prdx1 is expressed. To do this, the ORF
of Prdx1 was transfected into the MCF10A and MCF7
miR-510 expressing cells and cellular migration assessed
(Figure 6). As we have previously observed, the protein
levels of Prdx1 were reduced in the miR-510 expressing
cells (Figure 6A). In addition, we also see that Prdx1
protein and mRNA levels are increased in the miR-510
expressing cells when the Prdx1 ORF is transiently over-
expressed (Figure 6A, B), suggesting that Prdx1 protein
levels are restored to endogenous levels in the miR-510
expressing cells. We observed a small but significant
decrease in migration when PRDX1 was overexpressed
in scrambled control cells as well as a restoration of
migration to control levels in miR-510 expressing cells
when PRDX1 was co-expressed in both MCF10A and
MCF7 cells (Figure 6C, D).
miR-510 affects the redox function of Prdx1
Prdx1 is an antioxidant protein and, therefore, its pri-
mary function within the cell is involved with the regu-
lation of cellular redox response. To assess whether the
miR-510 mediated negative regulation of PRDX1 was
able to interfere with this primary function, we per-
formed cell viability assay after treatment with H2O2
(Figure 6E, F). MCF10A cells stably infected with miR-
510 showed increased sensitivity to treatment with
H2O2 when compared to the scrambled control
MCF10A cells (Figure 6E). To assess whether miR-510
was able to increase sensitivity to H2O2 to similar levels
as when PRDX1 is inhibited we performed cell viability
assay with MDA MB 231 cells stably infected with miR-
510 or scr control that were transiently transfected with
a short hairpin functionally validated to target PRDX1.
After 48 h, cells were either untreated or treated with
50 mM H2O2 for 24 h. Cell viability was assessed using
the trypan blue exclusion assay. Control cells were resis-
tant to this concentration of H2O2 and showed no cell
death. However, transfection with the shPRDX1 led to
an increase in sensitivity to H2O2, and we observed a 60
to 70% increase in cell death. Similarly cells overexpres-
sing miR-510 showed an increased sensitivity to H2O2,
showing a 30 to 40% increase in cell death. However, no
significant increase in sensitivity to H2O2 was observed
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Figure 4 PRDX1 is a direct target of microRNA 510. (A) Schematic representation of the predicted target site of miR-510 in the 3’UTR of
peroxiredoxin 1 (PRDX1) mRNA. The numbers 1 to 294 represent base pairs in the 3’UTR of PRDX1. Complementary base sequences are
highlighted in upper case letters. Western blot (B) and quantitative PCR (C and D) analysis of endogenous PRDX1 (B and C) and miR-510
(D) levels in the cell lines used in the study. GAPDH is shown as a loading control for western blot in B and is used for normalization in C and
D. (E) Luciferase activity of HEK293 cells transfected with pGL3 promoter luciferase reporter vector alone (EV), the PRDX1 3’UTR reporter construct
(PRDX 3’UTR) or PRDX1 3’UTR reporter construct mutated in the miR510 seed sequence binding site (PRDX mut). (F) Luciferase activity of MDA
MB 231 cells stably transfected with scrambled control (dark gray bars) or miR-510 (light gray bars) transiently transfected with reporter
constructs described in (E). All luciferase assays were normalized to Renilla luciferase activity. The data are expressed as the mean ± SD for three
experiments conducted in triplicate.
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in cells with shPRDX1 and miR-510 expression when
compared to either treatment alone.
Discussion
Since their discovery, microRNAs have been implicated in
many steps of cancer development and progression. They
have shown potential roles as predictors of treatment out-
comes and microRNA profiling of tumors may have the
ability to predict prognosis and identify tumor subtypes
[5]. The Croce group has shown that miRNAs are aber-
rantly expressed in human breast cancers and that this
expression correlated to multiple features of cancer,
including estrogen and progesterone receptor status, stage,
and indices of proliferation and invasion [7].
Currently in the literature there are few studies high-
lighting the role of miR-510. They include its involve-
ment in regulating expression of the serotonin receptor
type 3 in enterocytes of colonic mucosa, indicating a role
in irritable bowel syndrome [22,23], as well as identifying
elevated levels of miR-510 in Regulatory T cells (Tregs)
from Type 1 diabetic patients [24]. We have previously
published the role of miR-510 in promoting migration,
invasion and colony formation in breast cancer cells [15].
We also observed the levels of miR-510 to be elevated in
human breast tumor samples [15]. This study supports
the role of miR-510 functioning as an “oncomir”, causing
increased migration, invasion and colony formation of
non-transformed breast and non-invasive breast cancer
cells in vitro and promoting breast tumor growth in vivo.
Peroxiredoxin 1 (PRDX1) functions as a tumor suppres-
sor and has a cytoprotective role in breast cells [18,25].
PRDX1 contains a miR-510 seed sequence in its 3’UTR
and we have validated PRDX1 as a direct target of miR-
510 and have shown how regulation of PRDX1 by miR-
510 contributes to the migratory phenotype observed in
miR-510 over-expressing cells. Cao et al. showed that loss
of PRDX1 promotes PTEN oxidation and activation of
Akt [16]. Multiple targets of miR-510 are predicted to
directly target multiple negative regulators and effectors of
the Akt signaling pathway and, therefore, a potential
Figure 5 miR-510 regulates endogenous PRDX1 protein expression. (A) Western blot and (B) quantitative PCR analysis of endogenous
peroxiredoxin 1 (PRDX1) expression in MCF10A, MCF7 and MDA MB 231 cells stably infected with scrambled control (scr) or miR-510 (510).
(A) GAPDH is shown as a loading control. (B) Relative expression is normalized to GAPDH; scr - dark gray bars, miR-510 - light gray bars.
(C) Western blot and (D) quantitative PCR analysis of CAMA-1 and BT549 cells transiently transfected with increasing concentrations of antisense
oligonucleotides to miR-510(ASO-510) or antimiR-510 vector (anti-510). (C) ACTIN is shown for as a loading control. (D) Relative expression is
normalized to GAPDH; scr - dark gray bars, ASO-510 (150 nM) anti miR-510 (1 ug) - light gray bars, ASO-510 (450 nM) anti miR-510 (2 ug)- black
bars). Fold change in PRDX1 protein levels compared to scr control were quantified and are shown under each Western blot image.
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Figure 6 Functional effects of miR-510 mediated negative regulation of PRDX1. Western blot of PRDX1 protein expression (A), quantitative real
time PCR of peroxiredoxin 1 (PRDX1) mRNA levels (B) and quantified Pacman haptokinetic migration track assays (C) of miR-510 (510) or scrambled
control (scr) MCF10A cells transiently transfected with PRDX1 ORF (PRDX1; light gray bars in B) or empty vector (EV; dark gray bars in B). Western blots
are normalized to ACTIN and real time PCR to GAPDH. A low and high exposure of the same PRDX1 blot is shown as indicated. Quantitation of
haptokinetic migration track assays is of 10 independent tracks per experiment. (D) Transwell migration assay of MCF7 cells stably infected with miR-
510 or scrambled (scr) control transiently transfected with PRDX1 or empty vector (EV). (E) Trypan blue exclusion assay of miR-510 expressing (light
gray bars) or scrambled control (dark gray bars) MCF10A cells treated with increasing concentrations of hydrogen peroxide (H2O2) for 24 h. (F) Trypan
blue exclusion assay of miR-510 expressing or scrambled control (scr) MDA MB 231 cells transiently transfected with shPRDX1 vector or empty vector
(EV) control for 48 h before treatment with 0 (dark gray bars) and 50 μM (light gray bars) H2O2 for 24 h. Data in E and F are plotted as percent live cells
compared to untreated control. (E) *P < 0.05 compared to scr control. (F) *P < 0.05 compared to untreated control.
Guo et al. Breast Cancer Research 2013, 15:R70
http://breast-cancer-research.com/content/15/4/R70
Page 11 of 13
mechanism of miR-510-mediated increase in cell prolifera-
tion, migration, invasion and tumor growth could be
through hyperactivation of the Akt signaling pathway.
Indeed, we show in vitro that overexpression of Akt1 leads
to an increase in the expression of miR-510 and that inhi-
bition of Akt1 results in a decrease in the expression levels
of miR-510. Furthermore, we show in vivo that miR-510
expressing tumors have increased activation of the Akt
pathway as demonstrated by an increase in Akt phosphor-
ylation, suggesting that a positive feedback loop of this
pathway may be occurring in these cells. We have identi-
fied a novel role for PRDX1 in the inhibition of migration
and demonstrate here that miR-510 mediated negative
regulation of Prdx1 is able to inhibit both its role in migra-
tion as well as its more well-known role in cellular redox
response. However, further investigation of the mechanism
of miR-510 mediated negative regulation of PRDX1 is
necessary to fully understand their role in tumorigenesis
and breast cancer progression.
Conclusions
MicroRNA 510 is understudied; however, we have strong
evidence to support a pivotal role in breast cancer pro-
gression. A greater comprehension of the mechanisms
involved in miR-510 mediated tumor progression as well
as the direct targets mediating these effects are critical to
our understanding of its role in cancer. Exploring the
role of miR-510 in metastasis may also allow it to be used
as a biomarker and predictor of prognosis in patients,
providing the next step toward personalized treatment in
breast cancer.
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